Formosa Laboratories entered into a strategic partnership with Easywell Biomedicals, Inc. to jointly develop the TLX-054 injectable formulation. Through this collaboration, both parties will leverage their respective core expertise and resources to further strengthen the injectable product portfolios and expand into high-value and complex drug markets.